Sleptai has closed a Series A round of over 50 million U.S. dollars.

36 Kr has learned that recently, innovative biomedical company "Synphatec" has announced the completion of a Series A financing of more than 50 million USD. This round of financing is led by Decheng Capital, with Huatai Kingrui Fund and China Merchants Venture Capital as co-investors. Existing shareholders Morningside Ventures, Shunwei Capital and Qianju Capital have continued to increase their investment to support the company, while Vision Knight Capital acts as the exclusive financial advisor for this round of financing. The funds raised in this round will be mainly used to promote the clinical development of core pipelines SP-101 and SP-201, optimize the i-NaS and SynX dual technology platforms, and continuously expand the layout of innovative pipelines targeting major unmet clinical needs.